In This Section...

Founding Vision

Dr. Zaffaroni

Dr. Zaffaroni has founded many companies, among them Alexza Pharmaceuticals, all of which are based on applying innovative science to the treatment of disease and providing improvements over current modalities.

More about Dr. Zaffaroni

0 0

Publications

June 2013, Vol. 27, Issue 6, pp 479 - 489
Loxapine Inhalation Powder: A Review of its Use in the Acute Treatment of Agitation in Patients with Bipolar Disorder or Schizophrenia
Gillian Keating

Bipolar Disorders
April 2012
Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine
Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA, Kehne JH, Cassella JV

February 2012
The Pharmacokinetics and Pharmacodynamics of Zaleplon Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers
Michael J. Avram, Daniel A. Spyker, John H. Kehne and James V. Cassella

Journal of Aerosol Medicine and Pulmonary Drug Delivery
February 2011
Assessing the Temperature of Thermally Generated Inhalation Aerosols
Peter D. Noymer, Dan J. Myers, James V. Cassella, Ryan Timmons

Journal of Clinical Psychiatry
January 2011
Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Michael H. Allen, MD et al

January 2011
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
Michael D. Lesem, MD et al

Journal of Pharmaceutical and Biomedical Analysis
July 29, 2010
Forced Degradation of Fentanyl: Identification and Analysis of Impurities and Degradants
Garg et al

Journal of Aerosol Medicine and Pulmonary Drug Delivery
August 2010, Vol. 23, No. 4: 253-260
In Vitro Aerosol Deposition in the Oropharyngeal Region for Staccato Loxapine
Dinh et al

Vol 1 (2010): pp 11-20
The Staccato System: Inhaler Design Characteristics for Rapid Treatment of CNS Disorders
Noymer et al

Clinical Therapeutics
Vol. 32, No. 3 March 2010
Systematic Reviews of Assessment Measures and Pharmacologic Treatments for Agitation
S.L. Zeller et al

May 2010
The cardiovascular safety of inhaled loxapine.
Daniel A. Spyker, MD, PhD, Mildred D. Gottwald, PharmD, Robert S. Fishman, MD, James V. Cassella, PhD

May 2010
Efficacy Analyses in Patients with Schizophrenia or Bipolar Disorder
Robert S. Fishman, MD, Daniel A. Spyker, MD, PhD, James V. Cassella, PhD

The Journal of Clinical Pharmacology
2010; 50: 169-179
Pharmacokinetics of Loxapine Following Inhalation of a Thermally Generated Aerosol in Healthy Volunteers
Daniel A. Spyker, PhD, MD, Patrik Munzar, MD and James V. Cassella, PhD

September 2009, Vol. 4, No. 5, Pages 539-545 , DOI 10.2217/fnl.09.42
Drug Evaluation Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder
Kimberly Nordstrom‌†

APA 2009 (576kb PDF)
Inhaled Loxapine Rapidly Improves Acute Agitation in Patients with Bipolar Disorder
Robert Fishman, James Cassella, Daniel Spyker, AZ-004 Study Group

APA 2009 (524kb PDF)
Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients
James Cassella, Robert Fishman, Daniel Spyker, AZ-004 Study Group